Liquidia (NASDAQ:LQDA) CAO Sells $68,283.39 in Stock

Key Points

• Liquidia CAO Dana Boyle sold 1,581 shares at an average price of $43.19, generating $68,283.39. The sale was conducted under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards, leaving Boyle with 164,028 shares.
• Liquidia shares recently traded at $45.72, with a market capitalization of approximately $4.09 billion. The stock has ranged from $22.05 to $93.61 over the past year.
• Analysts maintain a mixed outlook, with the stock receiving an average rating of “Hold” and a consensus price target of $72.85. Recent targets range from $33 to $129, while the company reported sharply higher year-over-year revenue but slightly missed quarterly EPS estimates.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CAO Dana Boyle sold 1,581 shares of Liquidia stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $43.19, for a total value of $68,283.39. Following the transaction, the chief accounting officer directly owned 164,028 shares in the company, valued at approximately $7,084,369.32. The trade was a 0.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, October 12th, Dana Boyle sold 5,892 shares of Liquidia stock. The stock was sold at an average price of $28.48, for a total transaction of $167,804.16.

Liquidia Price Performance

NASDAQ LQDA traded up $0.28 on Wednesday, reaching $45.72. The company's stock had a trading volume of 2,235,400 shares, compared to its average volume of 2,280,838. Liquidia Corporation has a twelve month low of $22.05 and a twelve month high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The stock has a market cap of $4.09 billion, a PE ratio of 33.37, a PEG ratio of 0.37 and a beta of 0.61. The firm's 50 day moving average is $54.69 and its two-hundred day moving average is $54.15.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. During the same period in the prior year, the firm earned ($0.49) EPS. The business's revenue for the quarter was up 1842.1% on a year-over-year basis. As a group, sell-side analysts predict that Liquidia Corporation will post 2.05 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on LQDA shares. Royal Bank Of Canada set a $65.00 price objective on Liquidia in a research report on Thursday, October 15th. HC Wainwright boosted their target price on Liquidia from $58.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, October 15th. Needham & Company LLC reduced their target price on Liquidia from $72.00 to $58.00 and set a "buy" rating for the company in a report on Wednesday, October 14th. Wells Fargo & Company increased their price target on Liquidia from $30.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 14th. Finally, Piper Sandler set a $129.00 price target on Liquidia in a research note on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $72.85.

Institutional Trading of Liquidia

Large investors have recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of Liquidia by 12.3% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 17,400 shares of the company's stock worth $527,000 after buying an additional 1,900 shares during the period. Hanseatic Management Services Inc. raised its position in Liquidia by 2.0% during the third quarter. Hanseatic Management Services Inc. now owns 21,733 shares of the company's stock valued at $658,000 after buying an additional 435 shares during the period. Pinnacle Wealth Planning Services Inc. raised its position in Liquidia by 26.2% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,557 shares of the company's stock valued at $47,000 after buying an additional 323 shares during the period. Bryant Woods Investment Advisors LLC raised its position in Liquidia by 47.4% during the third quarter. Bryant Woods Investment Advisors LLC now owns 12,677 shares of the company's stock valued at $384,000 after buying an additional 4,077 shares during the period. Finally, Sterling Capital Management LLC lifted its stake in Liquidia by 839.1% in the 3rd quarter. Sterling Capital Management LLC now owns 2,329 shares of the company's stock worth $70,000 after acquiring an additional 2,081 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia's lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.